Sarcopenic Obesity and Cardiometabolic Health and Mortality in Older Adults: a Growing Health Concern in an Ageing Population.

IF 5.2 2区医学 Q1 ENDOCRINOLOGY & METABOLISM Current Diabetes Reports Pub Date : 2023-11-01 Epub Date: 2023-08-11 DOI:10.1007/s11892-023-01522-2

Sasiwarang Goya Wannamethee, Janice L Atkins

{"title":"Sarcopenic Obesity and Cardiometabolic Health and Mortality in Older Adults: a Growing Health Concern in an Ageing Population.","authors":"Sasiwarang Goya Wannamethee, Janice L Atkins","doi":"10.1007/s11892-023-01522-2","DOIUrl":null,"url":null,"abstract":"Purpose of review: Sarcopenic obesity (SO) is a growing public health problem in older adults. Whether SO confers higher risk of cardiometabolic disease and mortality than obesity or sarcopenia alone is still a matter of debate. We focus on recent findings on SO and cardiometabolic health and mortality in older adults.Recent findings: SO is associated with increased mortality compared to non-sarcopenic obesity, but similar mortality risk compared to sarcopenia without obesity. SO is associated with a higher risk of cardiovascular disease (CVD), diabetes, and physical disability than obesity or sarcopenia alone. SO, in the presence of diabetes, is associated with the highest risk of CVD and chronic kidney disease. A definition and diagnostic criteria for SO has recently been proposed (ESPEN and EASO). SO is associated with more adverse outcomes overall than sarcopenia or obesity alone. Future research is required to assess the impact of the new SO definition on health outcomes.","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":" ","pages":"307-314"},"PeriodicalIF":5.2000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640508/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Diabetes Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11892-023-01522-2","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/8/11 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Sarcopenic obesity (SO) is a growing public health problem in older adults. Whether SO confers higher risk of cardiometabolic disease and mortality than obesity or sarcopenia alone is still a matter of debate. We focus on recent findings on SO and cardiometabolic health and mortality in older adults.

Recent findings: SO is associated with increased mortality compared to non-sarcopenic obesity, but similar mortality risk compared to sarcopenia without obesity. SO is associated with a higher risk of cardiovascular disease (CVD), diabetes, and physical disability than obesity or sarcopenia alone. SO, in the presence of diabetes, is associated with the highest risk of CVD and chronic kidney disease. A definition and diagnostic criteria for SO has recently been proposed (ESPEN and EASO). SO is associated with more adverse outcomes overall than sarcopenia or obesity alone. Future research is required to assess the impact of the new SO definition on health outcomes.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

老年人肌肉减少性肥胖与心脏代谢健康和死亡率:老龄化人口中日益增长的健康问题。

综述目的:肌少性肥胖(SO)是老年人日益严重的公共卫生问题。SO是否会比肥胖或肌肉减少症本身带来更高的心脏代谢疾病和死亡率的风险仍然是一个有争议的问题。我们关注的是最近在老年人中关于SO和心脏代谢健康和死亡率的研究结果。最近的研究发现:与非肌肉减少性肥胖相比，SO与死亡率增加有关，但与没有肥胖的肌肉减少症相比，死亡率风险相似。与肥胖或肌肉减少症相比，SO与心血管疾病(CVD)、糖尿病和身体残疾的风险更高。在存在糖尿病的情况下，SO与心血管疾病和慢性肾脏疾病的最高风险相关。最近提出了SO的定义和诊断标准(ESPEN和EASO)。总的来说，与肌肉减少症或肥胖相比，SO与更多的不良后果相关。未来的研究需要评估新的SO定义对健康结果的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Diabetes Reports 医学 -

CiteScore

9.80

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： The goal of this journal is to publish cutting-edge reviews on subjects pertinent to all aspects of diabetes epidemiology, pathophysiology, and management. We aim to provide incisive, insightful, and balanced contributions from leading experts in each relevant domain that will be of immediate interest to a wide readership of clinicians, basic scientists, and translational investigators. We accomplish this aim by appointing major authorities to serve as Section Editors in key subject areas across the discipline. Section Editors select topics to be reviewed by leading experts who emphasize recent developments and highlight important papers published over the past year on their topics, in a crisp and readable format. We also provide commentaries from well-known figures in the field, and an Editorial Board of internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research.